2 December 2015 - A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more than $550,000 a year for each patient has been deemed too expensive by Britain's health cost watchdog NICE.

For more details, go to: http://www.reuters.com/article/2015/12/03/us-alexion-pharms-britain-idUSKBN0TM02420151203#plbG5tBD3Mr4Do5d.97